Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors - Concepedia

Concepedia

Publication | Open Access

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

DOI Full Paper Access

184

Citations

22

References

2015

Year

Adil Daud, Michelle T. Ashworth, Jonathan Strosberg, Jonathan W. Goldman, David S. Mendelson, Gregory M. Springett, Alan P. Venook, Sabine Loechner, Lee S. Rosen, David Parry,

Journal of Clinical Oncology

Abstract

MK-8776 was well tolerated as monotherapy and in combination with gemcitabine. Early evidence of clinical efficacy was observed. The recommended phase II dose is MK-8776 200 mg plus gemcitabine 1,000 mg/m(2) on days 1 and 8 of a 21-day cycle.

References

	Year	Citations

Page 1